From neuroprogression to neuroprotection: implications for clinical care.

Détails

ID Serval
serval:BIB_B9C6EC0BB5B2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
From neuroprogression to neuroprotection: implications for clinical care.
Périodique
Medical Journal of Australia
Auteur(s)
Berk M., Conus P., Kapczinski F., Andreazza A.C., Yücel M., Wood S.J., Pantelis C., Malhi G.S., Dodd S., Bechdolf A., Amminger G.P., Hickie I.B., McGorry P.D.
ISSN
0025-729X[print], 0025-729X[linking]
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
193
Numéro
4
Pages
S36-S40
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Bipolar disorder follows a staged trajectory in which persistence of illness is associated with a number of clinical features such as progressive shortening of the inter-episode interval and decreased probability of treatment response. This neuroprogressive clinical process is reflected by both progressive neuroanatomical changes and evidence of cognitive decline. The biochemical foundation of this process appears to incorporate changes in inflammatory cytokines, cortisone, neurotrophins and oxidative stress. There is a growing body of evidence to suggest that these markers may differ between the early and late stages of the disorder. The presence of a series of tangible targets raises the spectre of development of rational neuroprotective strategies, involving judicious use of current therapies and novel agents. Most of the currently used mood stabilisers share effects on oxidative stress and neurotrophins, while novel potentially neuroprotective agents are being developed. These developments need to be combined with service initiatives to maximise the opportunities for early diagnosis and intervention.
Pubmed
Web of science
Création de la notice
23/08/2010 14:29
Dernière modification de la notice
20/08/2019 16:27
Données d'usage